1
Ling Anthony, Plewe Michael Bruno, Truesdale Larry Kenneth, Lau Jesper, Madsen Peter, Sams Christian, Behrens Carsten, Vagner Josef, Christensen Inge Thøger, Lundt Behrend Frederik, Sidelmann Ulla Grove, Thøgersen Henning: Glucagon antagonists/inverse agonists. Novo Nordisk, Agouron Pharmaceuticals, November 23, 2000: WO/2000/069810 (5 worldwide citation)

A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hype ...


2
Teng Min, Truesdale Larry Kenneth, Bhumralkar Dilip, Kiel Dan, Johnson Michael D, Thomas Christine, Jorgensen Anker Steen, Madsen Peter, Olesen Preben Houlberg, Knudsen Liselotte Bjerre, Petterson Ingrid Vivika, Cornelis de Jong Johannes, Behrens Carsten, Kodra Janos Tibor, Lau Jesper: Non-peptide glp-1 agonists. Novo Nordisk, Agouron Pharma, October 24, 2001: EP1147094-A1 (2 worldwide citation)

Novel non-peptide GLP-1 agonists, pharmaceutical compositions comprising them, use of the non-peptide GLP-1 agonists for the preparation of pharmaceutical compositions and methods for the treatment and/or prevention of disorders and diseases wherein an activation of the human GLP-1 receptor is benef ...


3

4
Sun Eric T, Anderson Mark B, Anderes Kenna Lynn, Christie Lance Christopher, Do Quyen Quyen Thuy, Feng Jun, Goetzen Thomas, Hong Yufeng, Kraynov Eugenia Anatolievna, Li Haitao, Luthin David Robert, Paderes Genevieve D, Pathak Ved P, Rajapakse Ranjan Jagath, Shackelford Scott, Tompkins Eileen Valenzuela, Truesdale Larry Kenneth, Vazir Haresh: Non-peptide gnrh agents, pharmaceutical compositions and methods for their uses, and processes for preparing them. Agouron Pharma, March 31, 2004: EP1401427-A2

Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as we ...


5
Truesdale Larry Kenneth, Bychowski Richard A, Gonzalez Javier, Kuki Atsuo, Rajapakse Ranjan Jagath, Teng Min, Kiel Dan, Dhanoa Daljit S, Hong Yufeng, Chou Tso Sheng, Ling Anthony L, Johnson Michael David, Gregor Vlad Edward: Non-peptide antagonists of glp-1 receptor and methods of use. Agouron Pharma, October 4, 2001: EP1137413-A2

Non-peptide compounds that act as antagonists of the intestinal hormone glucagon-like peptide 1 (GLP-1) have a 9H- beta -carboline central motif. The compounds exhibit advantageous physical, chemical and biological properties and inhibit GLP-1 peptide binding to the GLP-1 receptor and/or prevent act ...


6

7
Truesdale Larry Kenneth, Bychowski Richard A, Gonzalez Javier, Kuki Atsuo, Rajapakse Ranjan Jagath, Teng Min, Kiel Dan, Dhanoa Daljit S, Hong Yufeng, Chou Tso Sheng, Ling Anthony L, Johnson Michael David, Gregor Vlad Edward: Non-peptide antagonists of glp-1 receptor and methods of use. Agouron Pharmaceuticals, Truesdale Larry Kenneth, Bychowski Richard A, Gonzalez Javier, Kuki Atsuo, Rajapakse Ranjan Jagath, Teng Min, Kiel Dan, Dhanoa Daljit S, Hong Yufeng, Chou Tso Sheng, Ling Anthony L, Johnson Michael David, Gregor Vlad Edward, HERBERT Toni Junell, June 15, 2000: WO/2000/033839

Non-peptide compounds that act as antagonists of the intestinal hormone glucagon-like peptide 1 (GLP-1) have a 9$i(H)-$g(b)-carboline central motif. The compounds exhibit advantageous physical, chemical and biological properties and inhibit GLP-1 peptide binding to the GLP-1 receptor and/or prevent ...


8
Ling Anthony, Plewe Michael Bruno, Truesdale Larry Kenneth, Lau Jesper, Madsen Peter, Sams Christian, Behrens Carsten, Vagner Josef, Christensen Inge Thoger, Lundt Behrend Frederik, Sidelmann Ulla Grove, Thogersen Henning: Glucagon antagonists/inverse agonists. Novo Nordisk, Agouron Pharma, March 6, 2002: EP1183229-A1

A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hype ...


9
Ling Anthony, Kuki Atsuo, Shi Shenghua, Plewe Michael Bruno, Feng Jun, Truesdale Larry Kenneth, May John, Kiel Dan, Madsen Peter, Sams Christian, Lau Jesper: Glucagon antagonists/inverse agonists. Novo Nordisk, Agouron Pharma, October 10, 2001: EP1140823-A1

Non-peptide compounds comprising a central hydrazide motif and methods for the synthesis thereof. The compounds act to antagonize the action of the glucagon peptide hormone.


10
Truesdale Larry Kenneth, Bychowski Richard A, Gonzalez Javier, Kuki Atsuo, Rajapakse Ranjan Jagath, Teng Min, Kiel Dan, Dhanoa Daljit S, Hong Yufeng, Chou Tso Sheng, Ling Anthony L, Johnson Michael David, Gregor Vlad Edward: Non-peptide antagonists of glp-1 receptor and methods of use. Agouron Pharmaceuticals, October 6, 2001: KR1020017007173

Non-peptide compounds that act as antagonists of the intestinal hormone glucagon-like peptide 1 (GLP-1) have a 9 H -β-carboline central motif. The compounds exhibit advantageous physical, chemical and biological properties and inhibit GLP-1 peptide binding to the GLP-1 receptor and/or prevent a ...